LXEO — Lexeo Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $154.03m
- $33.90m
- 24
- 27
- 33
- 17
Annual income statement for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.518 | 1.66 | 0.654 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.53 | 52.3 | 61.2 | 68.5 | 106 |
| Operating Profit | -5.01 | -50.6 | -60.5 | -68.5 | -106 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.15 | -50.6 | -59.3 | -66.4 | -98.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.15 | -50.6 | -59.3 | -66.4 | -98.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.15 | -50.6 | -59.3 | -66.4 | -98.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.15 | -50.6 | -59.3 | -66.4 | -98.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.192 | -2.05 | -2.4 | -2.69 | -3.09 |
| Dividends per Share |